Drug regulators in Europe have found no evidence that popular diabetes and weight reduction drugs similar to Ozempic and Wegovy are linked to the next risk of suicidal thoughts or actions.
This was announced by the Regulatory Committee of the European Medicines Agency Results of his review on Friday. This is the newest group to conclude that there isn’t a known link between a brand new class of obesity drugs and suicide.
In January, the US Food and Drug Administration declared a Preliminary examination showed no evidence of such a link, although the agency said it couldn’t rule out that “a small risk may exist” and that it could proceed to research the difficulty. A US study funded by the federal government also found that folks taking semaglutide, the drug in Ozempic and Wegovy, had a lower risk of suicidal thoughts than those taking older medications used to treat diabetes and obesity.
The review by European Union regulators was sparked last July by anecdotal reports that folks who used the drugs had thoughts of self-harm. Regulators examined studies, post-marketing data and other research related to drugs utilized in nearly a dozen drugs to treat the diseases. The group didn’t review information on tirzepatide, the drug utilized in medicines sold as Mounjaro and Zepbound.
Both agencies said they’d proceed to closely monitor reports of suicidal thoughts or actions in people stoning up referred to as GLP-1 receptor agonists. Patients taking the medications should report their mental health or other issues to their health care provider, officials said.
